Faeth Therapeutics (FTH) Cash from Investing Activities (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Cash from Investing Activities data on file, last reported at -$31.4 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 537.16% year-over-year to -$31.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 179.02% YoY) and the FY2025 annual result came in at $19.8 million, down 11.89% from the prior year.
• Cash from Investing Activities fell to -$31.4 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $19.5 million in Q2 2023 to a low of -$31.4 million in Q1 2026.
• A 5-year average of $5.8 million and a median of $8.3 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 2603.7% — and 2026, when it tumbled 537.16%.
• Tracing FTH's Cash from Investing Activities over 5 years: stood at $16.0 million in 2022, then plunged by 48.5% to $8.3 million in 2023, then sank by 138.14% to -$3.2 million in 2024, then jumped by 166.04% to $2.1 million in 2025, then slumped by 1610.62% to -$31.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$31.4 million (Q1 2026), $2.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.